Anti-Human OX40L (Oxelumab) – Dylight® 488
Anti-Human OX40L (Oxelumab) – Dylight® 488
Product No.: LT1311
Product No.LT1311 Clone R4930 Target TNFSF4 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names TNFSF4; GP34; CD252; TXGP1; CD134L; TNLG2B Isotype Human IgG1κ Applications FA , FC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Original antibody raised against Human OX40L Product Concentration 0.2 mg/ml Formulation This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Blue Laser (493 nm) RRIDAB_2893902 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Oxelumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? FA Additional Reported Applications For Relevant Conjugates ? B Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Oxelumab. Clone R4930 binds to Human OX40L (TNFSF4). This product is for research use only. Background Oxelumab is a human monoclonal antibody designed for the treatment of autoimmune diseases.3 Oxelumab recognizes human OX40L (TNFSF4). OX40L is a member of the tumor necrosis family and is the ligand for OX40 . The OX40/OX40L interaction generates an optimal T cell response and plays a significant role in determining the amount of memory T-cells remaining after the immune response.1 Therapeutic treatments with antibodies against TNFSF can sometimes result in serious side effects.2 More research is needed to understand the precise molecular mechanism of TNF inhibition. This cost-effective, research-grade Anti-Human OX40L (Oxelumab) utilizes the same variable regions from the therapeutic antibody Oxelumab making it ideal for research projects. Antigen Distribution OX40L is expressed in various cell types including antigen presenting cells, T-cells, vascular endothelial cells, mast cells, and natural killer cells. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Costimulatory Molecules . Immuno-Oncology . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Oxelumab biosimilars are used as analytical standards (calibrators) or reference controls in pharmacokinetic (PK) bridging ELISA assays to measure drug concentrations in serum by serving as the basis for generating the standard curve against which both biosimilar and reference drug concentrations are quantified. Context and supporting details:
Additional notes:
If you require more specific information regarding the preparation or validation of Oxelumab biosimilar standards in this context, or about ELISA design, please clarify. Standard Flow Cytometry Protocols for Oxelumab Biosimilar (e.g., PE or APC-Labeled) ValidationOxelumab is a human monoclonal antibody targeting OX40L (TNFSF4), a key costimulatory molecule involved in immune regulation. A biosimilar antibody with the same variable region (e.g., clone R4930), conjugated to fluorescent labels such as PE or APC, is commonly used in research to validate the expression levels or binding capacity of TNFSF4 on various cell types. Key Steps in Standard Flow Cytometry ProtocolsSample Preparation
Antibody Staining
Flow Cytometry Acquisition
Data Analysis
Notes and Best Practices
Summary Table: Key Parameters
References to Oxelumab Biosimilar UseThe Oxelumab biosimilar (clone R4930, APC-conjugated) is validated specifically for flow cytometry applications, with detailed lot-specific protocols available from manufacturers. Always refer to the manufacturer’s datasheet for the most current protocol and adjust as necessary for your experimental system. This protocol provides a general framework; optimization for specific cell types and experimental goals is recommended. Biopharma companies perform a comprehensive suite of analytical assays to confirm that a proposed biosimilar matches the originator (reference) biologic in both structure and function. These studies employ multiple orthogonal techniques to examine critical quality attributes (CQAs), addressing regulatory requirements for biosimilarity and providing "totality of evidence". Typical Analytical Assays for Biosimilar Characterization The main assays and their purposes include:
These methods are applied in a head-to-head comparison—using multiple lots of both the biosimilar and reference product—to ensure any variability is within allowable limits and does not impact clinical safety or efficacy. Role of Leinco Biosimilars in Analytical Assays Leinco Technologies manufactures recombinant antibodies and biosimilar proteins that are widely used as:
When conducting biosimilar comparability studies, biopharma companies often use Leinco's biosimilars as high-quality reference standards—especially when originator material is scarce, expensive, or when a qualified secondary reference is needed for robust assay calibration. This use is common in ELISA, SPR, and cell-based functional assays where precise, consistent controls are required to evaluate the activity and similarity of the biosimilar under study. In summary, biosimilar developers rely on a combination of state-of-the-art molecular, biophysical, and cell-based assays for regulatory-required analytical similarity assessments, often leveraging Leinco biosimilars as essential reagents to ensure rigor and reproducibility in these critical comparative analyses. References & Citations1. Mahmood,T. and Yang, P. (2012) N Am J Med Sci. 4(11): 533–536 2. Spicer, P. and Runkel, L. (2019) Expert Opin Investig Drugs. 28(2):99-106 3. Heo, YS. et al. (2014) Bio Design 2(2):55-61 Technical ProtocolsCertificate of Analysis |
Formats Available
